Crews Bank & Trust Invests $341,000 in Zoetis Inc. (NYSE:ZTS)

Crews Bank & Trust acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,090 shares of the company's stock, valued at approximately $341,000.

Several other large investors also recently made changes to their positions in the stock. State Street Corp increased its position in shares of Zoetis by 0.5% during the third quarter. State Street Corp now owns 19,779,344 shares of the company's stock worth $3,864,488,000 after acquiring an additional 95,856 shares in the last quarter. Geode Capital Management LLC grew its position in Zoetis by 1.8% in the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock valued at $2,030,813,000 after purchasing an additional 185,364 shares in the last quarter. Mizuho Securities USA LLC grew its position in Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock valued at $761,221,000 after purchasing an additional 194,542 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Zoetis by 10.6% in the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock valued at $569,834,000 after acquiring an additional 279,092 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on ZTS shares. Morgan Stanley cut their price target on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Stifel Nicolaus lowered their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis currently has an average rating of "Buy" and an average target price of $215.00.

Zoetis Price Performance

ZTS stock traded down $0.18 during mid-day trading on Tuesday, hitting $171.76. The stock had a trading volume of 1,521,650 shares, compared to its average volume of 2,627,942. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The firm has a market capitalization of $77.49 billion, a P/E ratio of 32.27, a P/E/G ratio of 2.72 and a beta of 0.90. The firm has a fifty day simple moving average of $169.48 and a 200 day simple moving average of $179.39.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm's revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.36 EPS. As a group, research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.16%. Zoetis's dividend payout ratio (DPR) is currently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.